Explain this page
Arphra AIPlain-English read on Viatris Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
- EXASExact Sciences Corporation$104.91$20.03B
- ROIVRoivant Sciences Ltd.$27.83$19.92B
- MRNAModerna, Inc.$45.37$17.99B
- RGCRegencell Bioscience Holdings Limited$29.12$14.4B
- BBIOBridgeBio Pharma, Inc.$68.56$13.29B
- NBIXNeurocrine Biosciences, Inc.$131.78$13.23B
- IONSIonis Pharmaceuticals, Inc.$75.28$12.44B
- RDYDr. Reddy's Laboratories Limited$13.72$11.42B
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.35% | -3.37% | +5.57% | +6.34% | +48.38% | +27.53% | +82.71% | +72.95% | +4.04% | -64.29% | +31654.20% |
Aftermarket
LiveLast trade
$15.88
216 sh
Bid
$15.82
2 sh
Ask
$15.93
400 sh
Spread
$0.110
Sector & industry today
LiveSectors
- Technology+0.67%
- Basic Materials+0.15%
- Communication Services+0.13%
- Real Estate-0.13%
- Industrials-0.48%
- Energy-0.58%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.85%
- Consumer Cyclical-0.85%
- Utilities-1.15%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - Specialty & Generic+0.32%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Coal+5.76%
- Consulting Services+5.28%
- Medical - Healthcare Information Services+5.23%
- Medical - Diagnostics & Research+4.96%
- REIT - Healthcare Facilities-3.49%
- Broadcasting-3.48%
- Software - Application+3.44%
- Advertising Agencies+3.24%
- Biotechnology+3.22%
Fair value
Football field →Weighted blend
$18.23
+15.31% vs spot
Recommendation
Buy
10 of 11 methods
Method spread
3bull6bear
±5% threshold
Analyst PT consensus: $15.25 (-3.54%)
Total assets
$37.19B
Total debt
$14.7B
Cash & equiv
$1.35B
Operating CF
$2.32B
Free cash flow
$1.94B
Buybacks
-$500.5M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$15.25
-3.54% upside
Low
$12.00
Median
$15.50
High
$18.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Why Viatris (VTRS) is a Top Growth Stock for the Long-Termzacks.com·May 12, 2026
- Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)seekingalpha.com·May 12, 2026
- Viatris to Present at the Bank of America Securities 2026 Healthcare Conferenceprnewswire.com·May 07, 2026
- Viatris Reports First-Quarter 2026 Financial Resultsprnewswire.com·May 07, 2026
- Viatris Announces Chief Financial Officer Transitionprnewswire.com·May 04, 2026
- Viatris Announces Chief Financial Officer Transitionprnewswire.com·May 04, 2026
- Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meetingprnewswire.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $3.7B | -$340.1M | $-0.30 |
| Q3 Sep 2025 | $3.76B | -$128.2M | $-0.11 |
| Q2 Jun 2025 | $3.58B | -$4.6M | $-0.00 |
| Q1 Mar 2025 | $3.25B | -$3.04B | $-2.55 |
| Q4 Dec 2024 | $3.53B | -$516.5M | $-0.43 |
| Q3 Sep 2024 | $3.75B | $94.8M | $0.08 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Campbell Paul officer: See Remarks | Sell | 21,350 | $283.54K | Mar 23, 2026 |
SIMMONS DAVID S director | Buy | 213 | $2.22K | Nov 03, 2025 |
Le Goff Corinne officer: Chief Commercial Officer | Sell | 7,032 | $72.04K | Sep 11, 2025 |
SIMMONS DAVID S director | Buy | 286 | $2.98K | Aug 27, 2025 |
Smith Scott Andrew director, officer: Chief Executive Officer | Buy | 22,000 | $219.74K | Aug 12, 2025 |
Smith Scott Andrew director, officer: Chief Executive Officer | Buy | 60,000 | $536.26K | May 12, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $14.3B | -$2.66B | -$3.51B | $-3.00 | -24.58% |
| FY 2024 | $14.74B | $10.1M | -$634.2M | $-0.53 | -4.30% |
| FY 2023 | $15.43B | $766.2M | $54.7M | $0.05 | +0.35% |
| FY 2022 | $16.26B | $1.61B | $2.08B | $1.71 | +12.78% |
| FY 2021 | $17.89B | -$34M | -$1.27B | $-1.05 | -7.10% |